Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcomain vivo
- 1 August 2003
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 64 (1-2) , 63-69
Abstract
Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affectedin vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9Lin vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40% in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsrin vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.Keywords
This publication has 29 references indexed in Scilit:
- Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigensJournal of Neurosurgery, 1999
- Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccineGene Therapy, 1999
- Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?Journal of Clinical Investigation, 1997
- The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-?, T-cell apoptosis, and the immune privilege of the brainBrain Research Reviews, 1995
- Modulation of the Immune Response by Transforming Growth Factor BetaInternational Archives of Allergy and Immunology, 1992
- Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumorsCancer Immunology, Immunotherapy, 1991
- Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells.Journal of Experimental Medicine, 1989
- The glioblastoma‐derived T‐cell suppressor factor/transforming growth factor beta2 inhibits the generation of lymphokineactivated killer (LAK) cellsInternational Journal of Cancer, 1988
- Suppression of Splenic Natural Killer Cell Activity in Rats with Brain TumorsNeurosurgery, 1988
- Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.Journal of Experimental Medicine, 1988